ID   Colo829/R
AC   CVCL_IW11
DR   cancercelllines; CVCL_IW11
DR   Wikidata; Q54814220
RX   PubMed=26365896;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Glyfs*51 (c.203_204delCG); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.493_634del142; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1137 ! COLO 829
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 12
//
RX   PubMed=26365896; DOI=10.1016/j.molonc.2015.08.003;
RA   Baenke F., Chaneton B., Smith M., van den Broek N., Hogan K., Tang H.-R.,
RA   Viros A., Martin M., Galbraith L., Girotti M.R., Dhomen N.,
RA   Gottlieb E., Marais R.;
RT   "Resistance to BRAF inhibitors induces glutamine dependency in
RT   melanoma cells.";
RL   Mol. Oncol. 10:73-84(2016).
//